Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-12 vs DOLISHALE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesic therapy for an extended period,Management of breakthrough pain in opioid-tolerant patients
Major Depressive Disorder (MDD),Generalized Anxiety Disorder (GAD),Obsessive-Compulsive Disorder (OCD),Panic Disorder,Post-Traumatic Stress Disorder (PTSD),Premenstrual Dysphoric Disorder (PMDD)
Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
Terminal elimination half-life is approximately 20–27 hours (range 13–44 hours) after transdermal patch removal; prolonged in elderly, hepatic impairment, and with continuous use due to drug accumulation in skin and adipose tissue.
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with Cr Cl <30 m L/min)
GFR 30-89 m L/min: start at 50% of usual initial dose; GFR <30 m L/min: avoid use or start at 50% of usual dose with cautious titration. Not recommended in dialysis patients.
e GFR 30-89 m L/min: 200 mg orally once daily. e GFR <30 m L/min or on dialysis: Not recommended.
WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; ABUSE POTENTIAL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISK OF MEDICATION ERRORS; and RISK OF SERIOUS HARM OR DEATH WITH CONCOMITANT USE OF CYP3A4 INHIBITORS. DURAGESIC is contraindicated in the management of acute or intermittent pain, or in opioid-non-tolerant patients. Accidental exposure to DURAGESIC may result in fatal respiratory depression.
Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdrawal syndrome, respiratory depression, and decreased fetal growth; avoid prolonged use near term.
DOLISHALE is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and craniofacial defects. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and renal impairment.
DURAGESIC-12 (fentanyl transdermal system) is indicated for opioid-tolerant patients only. Do not initiate in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-irradiated skin on flat surface such as chest, back, flank, or upper arm. Avoid heat sources (heating pads, hot tubs, fever) which increase absorption. Monitor for constipation and respiratory depression, especially at start and dose titration. Not for acute pain or post-op use in opioid-naive patients.
DOLISHALE (generic: perampanel) is a non-competitive AMPA receptor antagonist for partial-onset seizures. Monitor for serious psychiatric and behavioral adverse reactions including aggression, hostility, irritability, and suicidal ideation. Dose adjustment required in mild hepatic impairment; contraindicated in severe hepatic impairment. Use with caution in elderly due to falls risk. Serum concentration increased by strong CYP3A4 inducers; similarly, perampanel may decrease efficacy of oral contraceptives.
No interactions on record
No interactions on record
DURAGESIC-12 and DOLISHALE are distinct pharmacological agents. DURAGESIC-12 belongs to the Opioid Analgesic class and is primarily used for Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesic therapy for an extended periodManagement of breakthrough pain in opioid-tolerant patients. DOLISHALE belongs to the Opioid Analgesic class and is primarily used for Major Depressive Disorder (MDD)Generalized Anxiety Disorder (GAD)Obsessive-Compulsive Disorder (OCD)Panic DisorderPost-Traumatic Stress Disorder (PTSD)Premenstrual Dysphoric Disorder (PMDD). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DURAGESIC-12 carries a safety status of Category C, whereas DOLISHALE safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Fentanyl is primarily metabolized in the liver via CYP3A4-mediated N-dealkylation to norfentanyl, an inactive metabolite. Approximately 75% of the dose is excreted in urine, mainly as metabolites, with less than 10% as unchanged drug.
Primarily metabolized by CYP2D6 and CYP3A4 into active metabolites; undergoes hepatic conjugation.
Renal: approximately 75% as metabolites (primarily norfentanyl and other inactive metabolites) and <10% as unchanged fentanyl; fecal: approximately 9%; biliary: minor.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 80–85% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
98% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 6 L/kg (range 3–8 L/kg) after intravenous administration; high Vd indicates extensive tissue distribution and accumulation in fat and muscle.
0.8 L/kg (range 0.6-1.0), indicating extensive tissue distribution with high lipophilicity
Transdermal: approximately 92% relative to intravenous; absolute bioavailability is about 30–40% (due to first-pass metabolism, but transdermal bypasses hepatic first-pass, hence high relative bioavailability).
Oral: 60-70% (first-pass effect); Rectal: 50-60%; Intramuscular: 100%
Child-Pugh class A: start at 50% of usual initial dose; Child-Pugh class B: start at 25% of usual dose; Child-Pugh class C: avoid use due to extreme risk of toxicity.
Child-Pugh A: No adjustment. Child-Pugh B: 200 mg orally once daily. Child-Pugh C: Not recommended.
For pediatric patients aged 2-16 years currently receiving and tolerant to opioids (equivalent to at least 60 mg oral morphine/day): initial fentanyl dose (mcg/h) based on previous 24-hour opioid requirement using standard conversion; apply patch every 72 hours. For opioid-naive pediatric patients: not recommended.
Children ≥12 years: 5 mg/kg orally twice daily, maximum 200 mg/dose. Children <12 years: Not established.
Initiate at 50% of usual adult starting dose (e.g., 12 mcg/h every 72 hours) due to increased sensitivity and reduced clearance; titrate cautiously with longer intervals between dose adjustments.
Initiate at 200 mg orally once daily; titrate cautiously due to reduced renal function.
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
Avoid or limit grapefruit juice as it inhibits CYP3A4, increasing fentanyl levels and risk of adverse effects. No other significant food interactions. Alcohol should be avoided as it enhances central nervous system depression.
Avoid grapefruit and grapefruit juice as they may increase perampanel levels. No other significant food interactions.
Fentanyl transfers into breast milk; M/P ratio approximately 0.17-0.47. Caution: risk of infant sedation and respiratory depression. Consider benefits vs risks; avoid if infant is <3 months or has respiratory compromise.
No data on M/P ratio. DOLISHALE is excreted in human milk; potential for serious adverse reactions in nursing infants. Breastfeeding is contraindicated during therapy and for 7 days after last dose.
Pregnancy increases clearance of fentanyl by 35-50% in second and third trimesters; consider dose increase guided by pain response; postpartum clearance returns to prepregnancy levels within 48 h, requiring dose reduction.
Pharmacokinetic changes in pregnancy (increased clearance, altered protein binding) may reduce efficacy. Dose adjustment is not recommended due to teratogenicity; use is contraindicated. If unavoidable, therapeutic drug monitoring and dose escalation based on trough levels may be considered under strict supervision.
Apply patch to clean, dry, non-hairy skin; do not cut or damage the patch.,Do not expose patch to direct heat (heating pads, hot tubs, electric blankets).,Keep patch away from children and pets; dispose of used patches by folding adhesive side together and flushing down toilet.,Do not drink grapefruit juice as it may increase fentanyl levels.,Do not stop using patch suddenly as withdrawal symptoms may occur.,Report severe drowsiness, confusion, difficulty breathing, or constipation.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid driving or operating heavy machinery until you know how DOLISHALE affects you, as it may cause dizziness, drowsiness, and coordination problems.,Report any new or worsening depression, mood changes, aggression, or thoughts of suicide immediately.,Inform your doctor if you have liver disease, kidney problems, or are pregnant or planning to become pregnant.,Hormonal contraceptives may be less effective; use an additional non-hormonal method of birth control.,Do not consume alcohol while on DOLISHALE as it may worsen side effects.,Store at room temperature away from moisture and heat.